The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.
diabetes
empagliflozin
inflammation
liver
metabolome
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
12
2021
accepted:
04
01
2022
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
22
2
2022
Statut:
epublish
Résumé
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have shown the benefits of the SGLT2 inhibitor empagliflozin on improving liver steatosis and fibrosis in patients with T2DM. Metabolomic studies have been shown to be very useful to improve the understanding of liver pathophysiology during the development and progression of metabolic hepatic diseases, and because the effects of empagliflozin and of other SGLT2 inhibitors on the complete metabolic profile of the liver has never been analysed before, we decided to study the impact on the liver of male Zucker diabetic fatty (ZDF) rats of a treatment for 6 weeks with empagliflozin using an untargeted metabolomics approach, with the purpose to help to clarify the benefits of the use of empagliflozin at hepatic level. We found that empagliflozin is able to change the hepatic lipidome towards a protective profile, through an increase of monounsaturated and polyunsaturated glycerides, phosphatidylcholines, phosphatidylethanolamines, lysophosphatidylinositols and lysophosphatidylcholines. Empagliflozin also induces a decrease in the levels of the markers of inflammation IL-6, chemerin and chemerin receptor in the liver. Our results provide new evidences regarding the molecular pathways through which empagliflozin could exert hepatoprotector beneficial effects in T2DM.
Identifiants
pubmed: 35185578
doi: 10.3389/fphar.2022.827033
pii: 827033
pmc: PMC8847595
doi:
Types de publication
Journal Article
Langues
eng
Pagination
827033Informations de copyright
Copyright © 2022 Aragón-Herrera, Otero-Santiago, Anido-Varela, Moraña-Fernández, Campos-Toimil, García-Caballero, Barral, Tarazón, Roselló-Lletí, Portolés, Gualillo, Moscoso, Lage, González-Juanatey, Feijóo-Bandín and Lago.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Metabolites. 2021 Mar 22;11(3):
pubmed: 33809964
Mol Cell Endocrinol. 2022 Feb 5;541:111504
pubmed: 34763009
Diabetes Metab. 2018 Dec;44(6):457-464
pubmed: 30266577
FASEB J. 2019 Apr;33(4):5045-5057
pubmed: 30615497
World J Gastroenterol. 2014 Jul 14;20(26):8364-76
pubmed: 25024595
J Clin Endocrinol Metab. 2016 Mar;101(3):871-9
pubmed: 26709969
J Proteome Res. 2012 Apr 6;11(4):2521-32
pubmed: 22364559
Hepatol Commun. 2019 Feb 20;3(4):542-557
pubmed: 30976744
JHEP Rep. 2021 Mar 30;3(3):100284
pubmed: 34027340
Endocr Rev. 2019 Oct 1;40(5):1367-1393
pubmed: 31098621
Int J Mol Sci. 2021 Jun 13;22(12):
pubmed: 34199317
J Am Coll Cardiol. 2019 Jan 29;73(3):378-379
pubmed: 30678766
Heart Fail Rev. 2021 Nov;26(6):1421-1435
pubmed: 32314085
Liver Int. 2020 Feb;40 Suppl 1:82-88
pubmed: 32077613
Am J Physiol Regul Integr Comp Physiol. 2021 Feb 1;320(2):R95-R104
pubmed: 33175588
Obesity (Silver Spring). 2010 Jul;18(7):1460-3
pubmed: 19875987
Biochem Pharmacol. 2019 Dec;170:113677
pubmed: 31647926
Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):218-231
pubmed: 29074585
Trends Endocrinol Metab. 2021 Jul;32(7):500-514
pubmed: 33975804
Obes Rev. 2016 Jan;17(1):68-80
pubmed: 26597657
Drugs. 2018 Jul;78(10):1037-1048
pubmed: 29946963
Gut. 2021 May;70(5):940-950
pubmed: 32591434
Diabetes Obes Metab. 2020 Dec;22(12):2227-2240
pubmed: 32945071
Mol Cell Endocrinol. 2019 Dec 1;498:110539
pubmed: 31419466
Diabetol Metab Syndr. 2016 Jul 26;8:45
pubmed: 27462372
Cardiovasc Drugs Ther. 2018 Apr;32(2):213-222
pubmed: 29679303
Clin Chim Acta. 2020 May;504:146-153
pubmed: 32070869
Nat Commun. 2017 Apr 19;8:15010
pubmed: 28422089
Methods Mol Biol. 2012;933:103-23
pubmed: 22893404
Biochim Biophys Acta Biomembr. 2017 Sep;1859(9 Pt B):1558-1572
pubmed: 28411170
Diabetes. 2017 May;66(5):1172-1184
pubmed: 28246292
FASEB J. 2019 Oct 1;33(10):10986-10995
pubmed: 31284753
J Intern Med. 2022 Jan;291(1):11-31
pubmed: 34564899
Clin Chim Acta. 2021 Jun;517:41-47
pubmed: 33631197
Biochem Soc Trans. 2014 Oct;42(5):1447-52
pubmed: 25233430
Diabetologia. 2018 Oct;61(10):2108-2117
pubmed: 30132036
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Medicine (Baltimore). 2019 Aug;98(31):e16717
pubmed: 31374067
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Care. 2013 Aug;36(8):2331-8
pubmed: 23514731
Lipids. 2020 May;55(3):271-278
pubmed: 32255515
Diabetes Care. 2018 Aug;41(8):1801-1808
pubmed: 29895557
Biochim Biophys Acta. 2011 Dec;1811(12):1177-85
pubmed: 21745592
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
J Clin Invest. 2013 Jan;123(1):215-23
pubmed: 23221344
J Biol Chem. 2008 Mar 28;283(13):8258-65
pubmed: 18195019
PLoS One. 2014 Oct 23;9(10):e111348
pubmed: 25340546
Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1225-38
pubmed: 24714398
Int J Mol Sci. 2021 Jan 15;22(2):
pubmed: 33467546
Endocr Connect. 2021 Sep 20;10(9):1200-1211
pubmed: 34431786
J Endocrinol. 2018 Aug;238(2):R79-R94
pubmed: 29848608
Nutrients. 2019 Apr 08;11(4):
pubmed: 30965590
Metabolism. 2019 Dec;101:154001
pubmed: 31672448
J Lipid Res. 2012 Oct;53(10):2141-2152
pubmed: 22872753
J Proteomics. 2015 Sep 8;127(Pt B):275-88
pubmed: 25668325
J Proteome Res. 2010 Sep 3;9(9):4501-12
pubmed: 20684516
BMJ Open Diabetes Res Care. 2019 Oct 25;7(1):e000783
pubmed: 31749970
Annu Rev Nutr. 2004;24:345-76
pubmed: 15189125
J Endocrinol. 2018 Aug;238(2):91-106
pubmed: 29743343
Redox Biol. 2017 Oct;13:370-385
pubmed: 28667906
Hepatology. 2012 Jul;56(1):270-80
pubmed: 22271167
Diabetologia. 2021 Jul;64(7):1461-1479
pubmed: 33877366
Diabetes. 2009 Jan;58(1):203-8
pubmed: 18952834
Front Med (Lausanne). 2019 Sep 13;6:202
pubmed: 31616668
Free Radic Biol Med. 2019 Nov 20;144:293-309
pubmed: 31152791
Hepatology. 2017 Apr;65(4):1165-1180
pubmed: 27863448
Vascul Pharmacol. 2020 Oct - Nov;133-134:106779
pubmed: 32814163
Appl Physiol Nutr Metab. 2013 Mar;38(3):334-40
pubmed: 23537027
Sci Rep. 2017 Apr 24;7:46658
pubmed: 28436449
Int J Obes (Lond). 2019 May;43(5):989-998
pubmed: 30242234